ALPN — Alpine Immune Sciences Share News
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
Alpine Immune Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Alpine Immune Sciences Reports Fourth Quarter Results
Brief: Truveta And Alpine Immune Sciences Announce Strategic Partnership To Access Truveta’S Community To Accelerate Recruitment To Povetacicept Clinical Trials
Alpine Immune Sciences Inc expected to post a loss of 27 cents a share - Earnings Preview
Alpine Immune Sciences Inc expected to post a loss of 27 cents a share - Earnings Preview
SVB starts Alpine Immune with 'outperform'
Alpine Immune Sciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Alpine Immune Sciences Reports Third Quarter 2022 Financial Results
Alpine Immune Sciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Alpine Immune Sciences Inc expected to post a loss of 10 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Arista Networks, Planet Fitness, Tricida
U.S. STOCKS ON THE MOVE-TransDigm, Vaxcyte, Tricida
Alpine Immune falls after stopping enrollment in cancer drug studies
Brief: Alpine Immune Sciences Terminates Enrollment Of Davoceticept Clinical Studies
Brief: Alpine Immune Sciences And Cowen And Company, Llc Mutually Terminated The Sales Agreement Between The Parties
Alpine Immune Sciences falls after $100 mln stock deal
Alpine Immune Sciences edges up after $100 mln stock deal
Brief: Alpine Immune Sciences Announces Pricing Of $100 Million Public Offering
Brief: Alpine Immune Sciences Announces Proposed Public Offering